 |
82 |
 |
| |
Practical Considerations in Chronic Ischemic Heart Disease Management
|
|
 |
|
 |
|
|
83 |
|
| |
Angina treatment: Objectives
|
|
|
|
|
|
|
84 |
|
| |
Comprehensive management of myocardial ischemia
|
|
|
|
|
|
|
85 |
|
| |
CAD: Treatment challenges
|
|
|
|
|
|
|
86 |
|
| |
ACC/AHA guidelines: Chest pain evaluation
|
|
|
|
|
|
|
87 |
|
| |
ACC/AHA guidelines: Chronic stable angina treatment
|
|
|
|
|
|
|
88 |
|
| |
Substantial growth in PCI
|
|
|
|
|
|
|
89 |
|
| |
Stable CAD: PCI vs conservative medical management
|
|
|
|
|
|
|
90 |
|
| |
Major benefit of PCI: Angina symptom relief
|
|
|
|
|
|
|
91 |
|
| |
CAD progression: Major cause of post-revascularization angina
|
|
|
|
|
|
|
92 |
|
| |
Conditions limiting repeat revascularization
|
|
|
|
|
|
|
93 |
|
| |
Diabetes and PCI: Factors influencing outcome
|
|
|
|
|
|
|
94 |
|
| |
CARISA: Ranolazine benefits patients with and without diabetes
|
|
|
|
|
|
|
95 |
|
| |
CARISA: Ranolazine reduces A1C
|
|
|
|
|
|
|
96 |
|
| |
Selective vs routine catheterization: Cost reduction
|
|
|
|
|
|
|
97 |
|
| |
Chronic stable angina: Pharmacotherapy
|
|
|
|
|
|
|
98 |
|
| |
CRUSADE: Nonpharmacologic interventions at discharge
|
|
|
|
|
|
|
99 |
|
| |
CRUSADE: Discharge medications following UA/NSTEMI
|
|
|
|
|
|
|
100 |
|
| |
How important is IHD in women?
|
|
|
|
|
|
|
101 |
|
| |
AHA guidelines: Chest pain evaluation in women
|
|
|
|
|
|
|
102 |
|
| |
IHD vasculopathy: Gender differences
|
|
|
|
|
|
|
103 |
|
| |
Ischemia in women: Microvascular dysfunction
|
|
|
|
|
|
|
104 |
|
| |
Less obstructive CAD: Women vs men
|
|
|
|
|
|
|
105 |
|
| |
Women have more adverse outcomes vs men
|
|
|
|
|
|
|
106 |
|
| |
Higher incidence of major CV events in women
|
|
|
|
|
|
|
107 |
|
| |
Increased risk of death/MI in women with CAD
|
|
|
|
|
|
|
108 |
|
| |
CRUSADE: Gender and discharge medications
|
|
|
|
|
|
|
109 |
|
| |
Euro Heart Survey: Undertreatment of women
|
|
|
|
|
|
Resources
